相关实验视频
Updated: Jul 19, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.6K
抑制EPAC1可以保护心脏免受多克索鲁比诱导的毒性
Marianne Mazevet1, Anissa Belhadef1, Maxance Ribeiro1
1Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France.
eLife
|August 8, 2023
概括
抑制EPAC1可能会防止多克索鲁比引起的心脏损伤,这是常见的化疗副作用. 这种方法有望预防心脏毒性,而不会降低多克索鲁比的抗癌疗效.
科学领域:
- 分子生物学分子生物学
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 像多克索鲁比辛 (Dox) 这样的人类循环素是各种癌症的重要化疗药物.
- 多克斯的一个显著限制是其心脏毒性,可能导致扩张性心肌病和心力衰竭.
研究的目的:
- 调查cAMP (EPAC) 直接激活的交换蛋白在多克索鲁比诱导的心脏毒性的作用.
- 评估EPAC抑制对多克索鲁比心脏副作用的潜在心脏保护作用.
主要方法:
- 研究了多克索鲁比对DNA损伤和心肌细胞亡的影响.
- 测量周期性腺单酸盐 (cAMP) 水平和EPAC1活性后的多克索鲁比治疗.
- 在体内研究中利用药理学EPAC1抑制 (CE3F4) 和EPAC1淘汰 (KO) 的小鼠.
- 评估了多克索鲁比辛对人类癌症细胞系与EPAC1抑制的影响.
主要成果:
- 德克索鲁比辛诱导了DNA损伤,心肌细胞的亡,增加了cAMP,并增强了EPAC1活动.
- 抑制EPAC1,但不抑制EPAC2,减轻了多克索鲁比引起的心脏变化.
- 在野生类型小鼠中,多克索鲁比诱导的扩张性心肌病在EPAC1 KO小鼠中被预防.
- 抑制EPAC1增强了多克索鲁比杀死癌细胞的作用.
结论:
- EPAC1在多克索鲁比诱导的心脏毒性中发挥着关键作用.
- 抑制EPAC1是预防多克索鲁比引起的心脏损伤的潜在策略.
- 这种方法可以保持多克索鲁比的抗瘤活性,同时减少心脏毒性.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
622
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
22
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
22